Advertisement

Tissue concentration of systemically administered antineoplastic agents in human brain tumors

Abstract

The blood–brain-barrier (BBB) limits the penetration of many systemic antineoplastic therapies. Consequently, many agents may be used in clinical studies and clinical practice though they may not achieve therapeutic levels within the tumor. We sought to compile the currently available human data on antineoplastic drug concentrations in brain and tumor tissue according to BBB status. A review of the literature was conducted for human studies providing concentrations of antineoplastic agents in blood and metastatic brain tumors or high-grade gliomas. Studies were considered optimal if they reported simultaneous tissue and blood concentration, multiple sampling times and locations, MRI localization, BBB status at sampling site, tumor histology, and individual subject data. Twenty-Four studies of 19 compounds were included. These examined 18 agents in contrast-enhancing regions of high-grade gliomas, with optimal data for 2. For metastatic brain tumors, adequate data was found for 9 agents. Considerable heterogeneity was found in the measurement value, tumor type, measurement timing, and sampling location within and among studies, limiting the applicability of the results. Tissue to blood ratios ranged from 0.054 for carboplatin to 34 for mitoxantrone in high-grade gliomas, and were lowest for temozolomide (0.118) and etoposide (0.116), and highest for mitoxantrone (32.02) in metastatic tumors. The available data examining the concentration of antineoplastic agents in brain and tumor tissue is sparse and limited by considerable heterogeneity. More studies with careful quantification of antineoplastic agents in brain and tumor tissue is required for the rational development of therapeutic regimens.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Motl S, Zhuang Y, Waters CM, Stewart CF (2006) Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45:871

  2. 2.

    Cecchelli R, Berezowski V, Lundquist S et al (2007) Modelling of the blood-brain barrier in drug discovery, development. Nat Rev Drug Discov 6:650

  3. 3.

    Abbott N (2004) Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro, in silico models. Drug Discov Today Technol 1:407

  4. 4.

    Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295

  5. 5.

    Collins J, Dedrick R (1983) Distributed model for drug deliver to CSF and brain tissue. Am J Physiol Regul Integr Comp Physiol 245:R303

  6. 6.

    de Lange E, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood, brain. Clin Pharmacokinet 41:691

  7. 7.

    Pardridge W (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRX J Am Soc Exp NeuroTher 2:3

  8. 8.

    Miller DS, Bauer B, Hartz AMS (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60:196

  9. 9.

    Nies A (2007) The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254:11

  10. 10.

    Dallas S, Miller DS, Bendayan R (2006) Multidrug resistance-associated proteins: expression, function in the central nervous system. Pharmacol Rev 58:140

  11. 11.

    Norinder U, Haeberlein M (2002) Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev 54:291

  12. 12.

    Winkler D, Burden F (2004) Modelling blood-brain barrier partitioning using Bayesian neural nets. J Mol Graph Model 22:499

  13. 13.

    Basak S, Gute B, Drewes L (1996) Predicting blood-brain transport of drugs: a computational approach. Pharm Res 13

  14. 14.

    Clark DE (2003) In silico prediction of blood-brain barrier permeation. Drug Discov Today 8:927

  15. 15.

    Sarin H (2009) Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med 7

  16. 16.

    Groothuis D, Vick N (1982) Brain tumors and the blood-brain barrier. Trends Neurosci 5

  17. 17.

    Essig M, Weber M, Von Tengg-Kobligk H, et al (2006) Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 17

  18. 18.

    Blakeley JO, Olson J, Grossman SA et al (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51

  19. 19.

    Ma J, Pulfer S, Li S et al (2001) Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 61:5491

  20. 20.

    Claes A, Wesseling P, Jeuken J et al (2008) Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 7:71

  21. 21.

    Bickel U (2005) How to measure drug transport across the blood-brain-barrier. NeuroRX J Am Soc Exp NeuroTher 2:15

  22. 22.

    Sarin H, Kanevsky A, Wu H et al (2008) Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 6:80

  23. 23.

    Alavijeh M, Palmer A (2009) Measurement of the pharmacokinetics, pharmacodynamics of neuroactive compounds. Neurobiol Dis 37:38

  24. 24.

    Zhou Q, Gallo J (2005) In vivo microdialysis for PK, PD studies of anticancer drugs. AAPS J 7:E659

  25. 25.

    Blakeley J (2008) Drug delivery to brain tumors. Curr Neurol Neurosci Rep 8:235

  26. 26.

    Portnow J, Badie B, Chen M et al (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15:7092

  27. 27.

    Shinohara C, Matsumoto K, Kuriyama M et al (1994) Clinical pharmacokinetics of carboplatin, MCNU. Gan to kagaku ryoho. Cancer Chemother 21:1163

  28. 28.

    Whittle IR, Malcolm G, Jodrell DI, Reid M (1999) Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin. Br J Neurosurg 13:132

  29. 29.

    Gilbert M (2007) Tumor tissue delivery of celingitide after intravenous administration to patients with recurrent glioblastoma (GBM): preliminary data from NABTC protocol 03-02. Neuro-oncol 9:525

  30. 30.

    Nakagawa H, Fujita T, Izumoto S et al (1993) Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. I. Distribution within the central nervous system after intravenous, intracarotid infusion. J Neurooncol 16:61

  31. 31.

    Albrecht KW, Hamer PCdW, Leenstra S, et al (2001) High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin. Journal of Neuro-Oncology 53

  32. 32.

    Zucchetti M, Boiardi A, Silvani A et al (1999) Distribution of daunorubicin, daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 44:173

  33. 33.

    Raizer JJ, Abrey L, Lassman AB et al (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas, nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95

  34. 34.

    Bergenheim AT, Gunnarsson PO, Edman K et al (1993) Uptake, retention of estramustine, the presence of estratmustine binding protein in malignant brain tumours in humans. Br J Cancer 67:358

  35. 35.

    Zucchetti M, Rossi C, Knerich R et al (1991) Concentrations of VP16, VM26 in human brain tumors. Ann Oncol 2:63

  36. 36.

    Kiya K, Uozumi T, Ogasawara H et al (1992) Penetration of etoposide into human malignant brain tumors after intravenous, oral administration. Cancer Chemother Pharmacol 29:339

  37. 37.

    Stewart DJ, Richard MT, Hugenholtz H et al (1984) Penetration of VP-16 (etoposide) into human intracerebral, extracerebral tumors. J Neurooncol 2:133

  38. 38.

    Hofer S, Frei K (2007) Gefitinib concentrations in human glioblastoma tissue. J Neurooncol 82:175

  39. 39.

    Boogerd W, Tjahja IS, Sandt MMvd, Beijnen JH (1999) Penetration of idarubicin into malignant brain tumor tissue. J Neurooncol 44:65

  40. 40.

    Holdoff M, Supko J, Gallia GL et al (2009) Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 97:241

  41. 41.

    Kuhn JG (2008) Tumor sequestration of lapatinib. Neuro-oncol 10:783

  42. 42.

    Green RM, Stewart DJ, Hugenholtz H et al (1988) Human central nervous system, plasma pharmacology of mitoxantrone. J Neurooncol 6:75

  43. 43.

    Heimans JJ, Vermorken JB, Wolbers JB et al (1994) Paclitaxel (TAXOL) concentrations in brain tumor tissue. Ann Oncol 5:951

  44. 44.

    Fine RL, Chen J, Balmaceda C et al (2006) Randomized study of paclitaxel, tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 12:5770

  45. 45.

    Whittle IR, MacPherson JS, Miller JD, Smyth JF (1990) The disposition of TCNU (tauromustine) in human malignant glioma: phamacokinetic studies, clinical implications. J Neurosurg 72:721

  46. 46.

    Kuhn JG, Chang SM, Wen PY et al (2007) Pharmocokinetic and tumor distribution characteristics of temsirolimus. Clin Cancer Res 13:7401

  47. 47.

    van Tellingen O, Boogerd W, Nooijen WJ, Beijnen JH (1997) The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemother Pharmacol 40:330

  48. 48.

    Stewart DJ, Richard MT, Hugenholtz H et al (1984) Penetration of teniposide (VM-26) into human intracerebral tumors. J Neurooncol 2:315

  49. 49.

    Stupp R, Mason WP, Bent MJ et al (2005) Radiotherapy plus concomitant, adjuvant temozolomide for glioblastoma. N Engl J Med 352:987

  50. 50.

    Franceschi E, Cavallo G, Lonardi S et al (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96:1047

  51. 51.

    Vulpen Mv, Kal HB, Taphoorn MJ, Sharouni SYE (2002) Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 9:683

  52. 52.

    Martin I (2004) Prediction of blood-brain barrier penetration: are we missing the point? Drug Discov Today 9:161

Download references

Author information

Correspondence to Marshall W. Pitz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pitz, M.W., Desai, A., Grossman, S.A. et al. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 104, 629–638 (2011). https://doi.org/10.1007/s11060-011-0564-y

Download citation

Keywords

  • Brain tumor
  • Tissue concentration
  • Antineoplastic agent
  • Microdialysis
  • Blood–brain-barrier